PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Interferon beta – Market size and forecast 2018-2023
• Interferon alfa – Market size and forecast 2018-2023
• Other interferons – Market size and forecast 2018-2023
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer AG
• Biogen
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Merck Sharp & Dohme Corp.
PART 13: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Interferon beta – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Interferon beta – Year-over-year growth 2019-2023 (%)
Exhibit 22: Interferon alfa – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Interferon alfa – Year-over-year growth 2019-2023 (%)
Exhibit 24: Other interferons – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other interferons – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Prevalence of cancer types in the US
Exhibit 32: North America – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Approved biosimilars
Exhibit 39: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Decision framework
Exhibit 47: Treatment costs of interferon therapeutics used for treatment of various diseases
Exhibit 48: Side effects of interferon therapeutics
Exhibit 49: Recently approved substitutes to interferons
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Some interferon biosimilars in market
Exhibit 52: Vendor landscape
Exhibit 53: Landscape disruption
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: Bayer AG – Vendor overview
Exhibit 58: Bayer AG – Product segments
Exhibit 59: Bayer AG – Organizational developments
Exhibit 60: Bayer AG – Geographic focus
Exhibit 61: Bayer AG – Segment focus
Exhibit 62: Bayer AG – Key offerings
Exhibit 63: Bayer AG – Key customers
Exhibit 64: Biogen – Vendor overview
Exhibit 65: Biogen – Product segments
Exhibit 66: Biogen – Organizational developments
Exhibit 67: Biogen – Geographic focus
Exhibit 68: Biogen – Key offerings
Exhibit 69: Biogen – Key customers
Exhibit 70: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 71: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 72: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 73: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 74: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 75: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 76: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 77: Merck KGaA – Vendor overview
Exhibit 78: Merck KGaA – Business segments
Exhibit 79: Merck KGaA – Organizational developments
Exhibit 80: Merck KGaA – Geographic focus
Exhibit 81: Merck KGaA – Segment focus
Exhibit 82: Merck KGaA – Key offerings
Exhibit 83: Merck KGaA – Key customers
Exhibit 84: Merck Sharp & Dohme Corp. – Vendor overview
Exhibit 85: Merck Sharp & Dohme Corp. – Business segments
Exhibit 86: Merck Sharp & Dohme Corp. – Organizational developments
Exhibit 87: Merck Sharp & Dohme Corp. – Geographic focus
Exhibit 88: Merck Sharp & Dohme Corp. – Segment focus
Exhibit 89: Merck Sharp & Dohme Corp. – Key offerings
Exhibit 90: Merck Sharp & Dohme Corp. – Key customers
Exhibit 91: Validation techniques employed for market sizing
Exhibit 92: List of abbreviations
【掲載企業】
Bayer AG、Biogen、F. Hoffmann-La Roche Ltd.、Merck KGaA、and Merck Sharp & Dohme Corp
【免責事項】
https://www.marketreport.jp/reports-disclaimer